Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Abstract
Demonstrating the “clinical meaningfulness” of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid‐β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 04, 2020
- Source ID
- 10.1016/j.jalz.2019.09.074
Entities
People
- Colin L. Masters
- Dorene M. Rentz
- Elizabeth Mormino
- Kathryn V. Papp
- Keith A. Johnson
- On Behalf Of Collaborators From The Harvard Aging Brain Study, The Alzheimer's Disease Neuroimaging Initiative And The Australian Imaging, Biomarker And Lifestyle Study Of Aging
- Paul Maruff
- Rachel F Buckley
- Rebecca E. Amariglio
- Reisa A. Sperling
- Victor L. Villemagne
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Australia
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Edith Cowan University
- Eli Lilly and Company
- Harvard Medical School
- Hoffmann-La Roche
- National Health and Medical Research Council
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Science and Industry Endowment Fund
- Stanford University
- United States Department of Defense
- University of Melbourne